Keryx Biopharmaceuticals, Inc. to Host Conference Call on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2014 Financial Results

NEW YORK, May 5, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, May 8, 2014 at 8:00 a.m. EDT to discuss results for the first quarter of 2014 and provide an update on the business.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com , for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients suffering from chronic kidney disease (CKD). In the United States, ferric citrate coordination complex is currently under review by the Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in dialysis-dependent CKD patients, where, pending approval, it will be marketed as Zerenex™ by Keryx. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it will be marketed as Riona ® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

About Zerenex™

Zerenex™ (ferric citrate coordination complex), is an oral, ferric iron-based phosphate binder. Keryx has completed a U.S.-based phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in dialysis-dependent CKD patients, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. The company's New Drug Application (NDA) is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014. Keryx has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), seeking the approval of Zerenex as a treatment of hyperphosphatemia in patients with all stages of CKD and that application is currently under review.

KERYX CONTACT: Amy Sullivan Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 508.479.3480 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CatsOnly: Building Community with Feline-Centric Care

Updated Category News Views 36

Cats Only: Not Just Another Vet Office Sometimes, a new kind of passion-driven initiative gets your attention. That's where CatsOnly™ steps in—a feline-exclusive clinic that’s not about the bottom line but about building connections and elevating that ultimate feline care game. Their latest gig, dubbed Ginger’s Giving Season, is all about bridging the gap between...

Continue Reading
Paulex Bio's Grant Fuels Bold Diabetes Research Push

Updated Category News Views 94

Cracking the Diabetes Code: A New Hope Emerging It ain't every day you hear about a biotech outfit snagging an NIH Fast-Track grant with the potential to upend diabetes treatment, but Paulex Bio's recent score turns heads. Their brainchild, PAL-119, promises to tackle diabetes not by slapping a band-aid on symptoms, but by getting to the rotten core of the disease: the...

Continue Reading
Kia's Landmark Triple Win at 2026 Car Awards

Updated Category News Views 85

Kia Makes History Well, folks, Kia has pulled off what many might have thought impossible. They snagged not one, not two, but three of Germany's Golden Steering Wheel awards. That's a real hat trick and a first for any non-European auto brand. With competition hotter than a stolen Tesla, Kia's not just keeping pace but setting it. The Golden Steering Wheel is one of those...

Continue Reading
Resideo's AI-Powered Pro-IQ™ Predict: HVAC Revolution

Updated Category News Views 314

Is AI the Savior for HVAC Breakdowns? You ever been stuck on a freezing night with a busted heater? It's a classic tale: equipment goes south just when you need it most. But what if someone told you AI could catch HVAC issues before they send you running for the wool socks? Enter Resideo Technologies' latest brainchild, Pro-IQ™ Predict. This isn't some run-of-the-mill...

Continue Reading
Florida's Insurance Premiums: Why They Keep Skyrocketing

Updated Category News Views 61

What’s Driving Up These Premiums? If you’ve ever felt like your wallet gets lighter every time you pay your insurance premium, welcome to the club. It seems like the cost of insurance in Florida is like a runaway train. But don't just blame the hurricanes. Yeah, they definitely play their part, but there’s a bigger picture lurking behind those price tags. Weather...

Continue Reading
Dixie Group Gears Up for Q3 Earnings Call Reveal

Updated Category News Views 165

Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...

Continue Reading
Ceipal Ora: AI Revolution for Staffing Firms Begins

Updated Category News Views 65

Staffing Game Changer: Enter Ceipal Ora Folks in the staffing arena, hold onto your hats—Ceipal's rolling out something that could turn the tables. This new AI hotshot, Ceipal Ora, claims to be not just another AI patch on an old coat but the whole new garment itself. It's not just some afterthought glued to a platform; it's the glue holding the operations together,...

Continue Reading
CeQur Revolutionizes Insulin Delivery with Wearable Patch

Updated Category News Views 67

A Patch to Simplify Mealtime Insulin So, it turns out CeQur is stepping up to the plate with their new wearable insulin patch called CeQur Simplicity. They just rolled it out nationally, and it's not your grandmother's insulin delivery method—this one sticks around for a whole week with some nifty up-to-1-unit dosing. If you're shoving insulin needles or pens into your...

Continue Reading
Yeastar 2026 Summit: AI, Growth, and Global Vision

Updated Category News Views 32

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Continue Reading
Otus Earns Top Spot in Education AI at Innovation Awards

Updated Category News Views 85

Acknowledging AI's Growing Role in Education Times are changing, and the classroom ain't what it used to be. Enter Otus, a platform that's breaking the mold by bringing artificial intelligence smack dab into K-12 education. They've bagged the 2026 SmartBrief Innovation Award in AI within the Education category. Clocking in at serving nearly 100 school districts, it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Canine Cancer Treatment Through Innovation

Updated Category News Views 167

Revolutionizing Canine Cancer Care Through Innovation The world of veterinary medicine has seen incredible progress in caring for dogs with cancer. Thrive Pet Healthcare is making significant efforts to improve the quality of care for these pets. Their partnership with FidoCure, a leader in canine oncology, highlights their dedication to helping pet owners access...

Continue Reading
BioAtla to Showcase Innovative Cancer Therapies at Major Events

Updated Category News Views 189

BioAtla to Showcase Innovative Cancer Therapies at Major Events BioAtla, Inc. (Nasdaq: BCAB), a prominent player in the biotechnology sector, focuses on advancing Conditionally Active Biologic (CAB) antibody therapeutics aimed at treating solid tumors. With a commitment to innovation and patient care, the company announced that two of its research abstracts have been...

Continue Reading
Liberty Star Minerals' Geophysical Breakthrough in Gold Discovery

Updated Category News Views 158

Revelation in Gold Exploration Liberty Star Minerals, an innovative exploration company, has recently made headlines with the successful induced polarization (IP) and resistivity testing at the Red Rock Canyon Gold Project. This project is a part of their extensive Hay Mountain Project in southeastern Arizona. These tests are pivotal in the ongoing search for strategic...

Continue Reading
Malibu Boats Celebrates Another Award for the Wakesetter 23 LSV

Updated Category News Views 135

Malibu Boats Wakesetter 23 LSV Triumphs Again Malibu Boats, Inc. (NASDAQ: MBUU) continues to solidify its position as the leader in the watersports boating industry. The iconic Malibu Wakesetter 23 LSV has been awarded the prestigious title of Wakesurf and Wakeboard Boat of the Year for the sixth consecutive year by the WakeWorld Riders Choice Awards. This remarkable...

Continue Reading
Alto Neuroscience Faces Deadline for Securities Fraud Lawsuit

Updated Category News Views 100

Understanding Alto Neuroscience's Legal Challenges Alto Neuroscience, Inc. (NYSE: ANRO) is currently in the spotlight due to a securities fraud class action lawsuit filed on behalf of its investors. The company has faced scrutiny regarding its initial public offering (IPO) and claims that misrepresentations were made about its flagship product, ALTO-100, a treatment...

Continue Reading